WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN ), reiterates investor confidence and estimated asset value over $10 billion.

During the fireside chat, Drs. Campagna and Nikodem will highlight recent corporate updates, progress on lanifibranor and the Phase III NATiV3 trial in MASH and discuss the Company’s broader R&D ...

DALLAS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BHIANT, the workforce development arm of BioNTX, is charting new ground in biotechnology talent development and industry collaboration, strengthening North ...

Photo: Esteworld Opens Its First Representative Office in the UK in London ...

This facility is designed to provide expanded capacity and operational security as Kraig Labs scales up its recombinant spider silk manufacturing. The site will play a key role in supporting the ...

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ...

Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and ...

MediPharm Labs executive management team will also host a conference call and webcast on Thursday, August 14 th, 2025 at 10:00 a.m. (Eastern time) to discuss the Company’s financial results. North ...

This data was produced from a multi-center study that enrolled 125 patients. The data demonstrates that VIVO was over 94% accurate, assisted physicians in determining workflow when used pre-procedure, ...

Basel, Switzerland – August 11, 2025 – FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the dosing of the first patient in a ...

WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced its results for the second quarter of fiscal 2025 ended June 30, 2025 in this Earnings Press Release and ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported ...